TERRANET
4.1.2020 13:22:09 CET | Business Wire | Press release
At next week’s International CES 2020, Terranet will demonstrate VoxelFlow - a 3D motion perception technology capable of detecting and classifying objects far more accurately and exponentially faster than Lidar. Terranet’s demo is timely considering Tesla CEO Elon Musk shocked the press just last April with his remarks: “Lidar is a fool’s errand. Anyone relying on Lidar is doomed. Doomed!” In a bold move, Swedish-headquartered Terranet plans on backing up Musk’s claims that Lidar is merely a dangerous shortcut to image recognition – a perilous reliance if that’s what the promised fully autonomous cars of the future will continue to use.
Invented by Dirk Smits, VoxelFlow was built upon the understanding that today’s camera-based computer vision and artificial intelligence navigation systems are simply too slow and subject to fundamental speed limits of perception using a frame based approach. Lidar has limited resolution and slow scanning rates, making it nearly impossible to distinguish between, for example, a fixed lamppost and a running child.
The underlying problem with Lidar or any existing camera/computer vision technology is that it cannot detect vulnerable road users with low latency. VoxelFlow on the other hand classifies dynamic moving objects at extremely low latency using very low computational power, producing 10 million 3D points per second, resulting in rapid edge detection without motion blur. The iPhone’s ‘selfie’ camera pales in comparison, producing a mere 33,000 light points per frame. Put into context, standard vehicles today and even those with autonomous driving roadmaps in place don’t use cameras much stronger than that of the iPhone’s selfie camera.
VoxelFlow’s capabilities are especially relevant considering harrowing statistics indicating that 80% of all crashes and 65% of all near-crashes involve driver inattention within the last 3 seconds of the crash. By providing life-saving decision making in milliseconds versus seconds, Terranet envisions transforming the pre-crash inattention that today accounts for roughly 1.35M road accident deaths into a forgotten collision-free swerve on the road.
“Terranet succeeding in proving VoxelFlow as a serious and necessary contender to Lidar is just the kind of shake-up the oft self-congratulatory autonomous driving community needs to kick start the new decade and save lives,” says Terranet CEO, Pär-Olof Johannesson.
To schedule a viewing of the VoxelFlow demo during CES, please contact Christina Björnström at +1-818-672-6954 or contact Lena Hägvall via email lena.hagvall@terranet.se
www.terranet.se
https://vimeo.com/377730923
ABOUT TERRANET
Terranet design radio and vision based ADAS software platforms for collision avoidance. Terranet is headquartered in Lund, Sweden, with offices in Stuttgart and California. Terranet Holding AB (publ) is listed on Nasdaq First North Premier.
Appointed Certified Adviser to Terranet Holding AB (publ) is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom